mammalian target of rapamycin inhibitor Archives - Erwotex.net

No Benefit Seen With Everolimus in Early Breast Cancer

08/03/2021 biologic therapy, breast, Breast cancer, cancer, carcinoma, chemotherapy, endocrine therapy, HER2 negative breast cancer, HER2- breast cancer, Hormone Therapy, inhibitor (mammalian target of rapamycin), malignant breast neoplasm, malignant neoplasia, mammalian target of rapamycin inhibitor, mtor inhibitor, selective estrogen receptor modulator (serm), tamoxifen, target-of-rap, targeted therapy, tor inhibitor

Adding everolimus to adjuvant hormone therapy for early ER+, HER2- breast cancer does not offer any benefit over hormone therapy